At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HRMY Harmony Biosciences Holdings, Inc.
Post-Mkt 10-14 18:50:19 EDT
37.51
+0.48
+1.30%
盘后37.51
+0.000.00%
17:40 EDT
High38.31Low36.92Vol972.23K
Open37.16D1 Closing37.03Amplitude3.75%
Mkt Cap2.18BTradable Cap1.95BTotal Shares58.24M
T/O36.67MT/O Rate1.87%Tradable Shares52.10M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mizuho positive on Harmony Biosciences CEO transition
TIPRANKS  ·  10-12 22:20
Mizuho positive on Harmony Biosciences CEO transition
Harmony Biosciences Price Target Maintained with a $50.00/Share by Needham
Dow Jones  ·  10-12 21:37
Harmony Biosciences Price Target Maintained with a $50.00/Share by Needham
US Stocks on the MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences
Reuters  ·  10-12 21:03
US Stocks on the MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences
Harmony Biosciences Names COO Peter Anastasiou CEO Effective Jan. 1, 2027
Reuters  ·  10-12 19:00
Harmony Biosciences Names COO Peter Anastasiou CEO Effective Jan. 1, 2027
Harmony Biosciences - Jeffrey M. Dayno to Retire as CEO and Step Down from Board at Year-End 2026
THOMSON REUTERS  ·  10-12 19:00
Harmony Biosciences - Jeffrey M. Dayno to Retire as CEO and Step Down from Board at Year-End 2026
Harmony Biosciences - Reiterates Full-Year 2026 Wakix Net Revenue Guidance of $1 Bln-$1.04 Bln
THOMSON REUTERS  ·  10-12 19:00
Harmony Biosciences - Reiterates Full-Year 2026 Wakix Net Revenue Guidance of $1 Bln-$1.04 Bln
Harmony Biosciences - on Track to Report BP-205 Mad Study Data in Q4 2026
THOMSON REUTERS  ·  10-12 19:00
Harmony Biosciences - on Track to Report BP-205 Mad Study Data in Q4 2026
Harmony Biosciences - Appoints Peter Anastasiou as President, CEO, and Board Member Effective Jan 1, 2027
THOMSON REUTERS  ·  10-12 19:00
Harmony Biosciences - Appoints Peter Anastasiou as President, CEO, and Board Member Effective Jan 1, 2027
Press Release: Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Dow Jones  ·  10-12 19:00
Press Release: Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Harmony BioSciences' Wakix Franchise, Pipeline Offer Multiple Value Drivers, Oppenheimer Says
MT Newswires Live  ·  10-08
Harmony BioSciences' Wakix Franchise, Pipeline Offer Multiple Value Drivers, Oppenheimer Says
Why Harmony Biosciences Holdings (HRMY) Is Getting Attention Today
Simply Wall St.  ·  10-07
Why Harmony Biosciences Holdings (HRMY) Is Getting Attention Today
Harmony Biosciences Presents Phase 3 HBS-301 Trial Data in Narcolepsy, Idiopathic Hypersomnia at European Narcolepsy Days
Reuters  ·  10-01
Harmony Biosciences Presents Phase 3 HBS-301 Trial Data in Narcolepsy, Idiopathic Hypersomnia at European Narcolepsy Days
Deutsche Bank Lifts Price Target on Harmony Biosciences Holdings to $42 From $39, Keeps Hold Rating
MT Newswires Live  ·  10-01
Deutsche Bank Lifts Price Target on Harmony Biosciences Holdings to $42 From $39, Keeps Hold Rating
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY), BioNTech SE (BNTX) and Biogen (BIIB)
TIPRANKS  ·  09-26
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY), BioNTech SE (BNTX) and Biogen (BIIB)
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)
TIPRANKS  ·  09-24
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)
Harmony Biosciences CMO Budur Kumar Disposes of USD 1,656,098.48 in Common Shares
Reuters  ·  09-19
Harmony Biosciences CMO Budur Kumar Disposes of USD 1,656,098.48 in Common Shares
Harmony Biosciences CMO Budur Kumar Disposes of USD 1.43 Million in Common Shares
Reuters  ·  09-10
Harmony Biosciences CMO Budur Kumar Disposes of USD 1.43 Million in Common Shares
Harmony Biosciences to Join Cantor Global Healthcare Conference Fireside Chat
Reuters  ·  08-27
Harmony Biosciences to Join Cantor Global Healthcare Conference Fireside Chat
Harmony Biosciences Price Target Announced at $60.00/Share by Wolfe Research
Dow Jones  ·  08-26
Harmony Biosciences Price Target Announced at $60.00/Share by Wolfe Research
Harmony Biosciences: Strengthening Core Business and Pipeline Support Unchanged $55 Price Target and Buy Rating
TIPRANKS  ·  08-12
Harmony Biosciences: Strengthening Core Business and Pipeline Support Unchanged $55 Price Target and Buy Rating

Introduction

Company Name.
Harmony Biosciences Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Issue price:
--